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Rapport de synthèse 
But: la resténose intra-stent au sirolimus (SAS) reste un problème clinique. Parmi 
les diverses approches thérapeutiques disponibles aujourd'hui aucune n'a la 
primauté car les résultats à moyen terme restent relativement médiocres. 
Méthodologie: les patients souffrant d'une resténose intra-SAS chez lesquels un 
second SAS a été implanté comme traitement de cette resténose ont été inclus 
dans ce registre. Lors d'ischémie clinique ou électrique après implantation d'un 
SAS les malades chez lesquels l'angioplastie au ballon seul ne donnait pas un 
résultat satisfaisant ont bénéficié de l'implantation d'un stent actif dans un stent 
actif. 
Résultats: vingt-sept patients sont inclus dans ce registre. La resténose était de 
type focale dans 34% des cas, diffuse dans 59% des cas et proliférative dans 7% des 
cas. La procédure a été un succès chez tous les patients sans complications aiguës 
durant l'hospitalisation. A 14±7 mois, on dénombre 8 (30%) événements cardiaques 
majeurs (1 mort, 1 infarctus du myocarde, 4 revascularisations additionnelles de la 
lésion, 1 revascularisation additionnelle du vaisseau cible). Un patient a subi un 
pontage aorte-coronarien. Dix-neuf patients (70%) ont évolué sans aucun problème. 
Conclusion: en conclusion, l'implantation d'un SAS pour traiter une resténose 
intra-SAS est réalisable avec un très bon résultat immédiat. Cependant, l'incidence 
d'un événement cardiaque majeur reste élevée à long terme. 
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Abstract: Restenosis after sirolimus-eluting stents (SES) remains a clinical problem. We report our experience with the use a 
second SES in the first SES to treat in-SES restenosis. Twenty-seven patients with in-SES restenosis were included in the reg-
istry. In-SES restenosis was focal in 34%, diffuse in 59% and proliferative in 7%. The procedure was success:ful in ail patients 
without any acute in-hospital complications. During a mean follow-up of 14± 7 months MACE occurred in 8 patients (30%), 
(1 death, 1 myocardial infarction, 4 target lesion revascularisation, 1 target vessel revascularisation and 1 patient underwent 
CABG). Nineteen patients (70%) had an event-free outcome. In conclusion SES placement to treat in-SES is safe and feasible 
and could be considered as a therapeutic option. However the incidence of MACE remains high on a long-term period. 
The use of stents has significantly improved the outcome of percutaneous coronary interventions (PCI) (1,2). However, 
despite major advances in angioplasty and stenting, in-stent restenosis remains a major limitation. Recently, drug-eluting 
stents and especially sirolimus-eluting stents (SES) have emerged as a very promising approach in preventing restenosis, 
and several different compounds have been shown to have a major impact on both the angiographie and the clinical outcome 
(6-9). However, even after drug eluting stents implantation in-stent restenosis (ISR) remains and represents a clinical chal-
lenge. Several approaches have been proposed to deal with ISR like plain old balloon angioplasty (POBA), rotational 
atherectomy, brachytherapy (1-3). Few reports are actually available about the use of SES in SES for ISR treatment. We 
report our experience about the use SES for treating an ISR after SES implantation. 
Method 
Between March 2004 and April 2006 all patients with in-SES restenosis that were not optimally treated 
by plain old balloon angioplsty received a second SES (Cypher and Cypher select, Cordis, Miami Lakes, 
Florida) within the first one (re-SES). The procedural data of these consecutive patients were included 
in a registry. The institutional review board ofboth participating institutions approved the study. Eligible 
patients provided written informed consent. The study complied with the Declaration of Helsinki 
regarding investigations in humans. 
Procedures were performed via a femoral artery approach. A 5 or 6 French guiding catheter was used. All 
patients were pre-treated with aspirin 1 OO mg/day. Intravenous heparin (70 U/kg) was given at the beginning 
and a 300 or 600 mg loading dose of clopidogrel was administered at the end of the procedure. Standard 
interventional techniques were used to treat the patients and performed at the discretion on the in-charge 
operator. Intravascular ultrasound was not used. Angioplasty with a «power-grip» balloon was performed in 
all patients before implantation of the second new SES stent. A successful procedure was defined, as a 
residual stenosis <20 percent and the absence of major adverse cardiac event during the in-hospital stay. 
After the procedure, patients were monitored in an intermediate care unit. CK, CK-MB values were 
measured at least once on the moming of the following day. A 12 lead ECG was recorded at the end of 
the procedure for all patients, and further tracings were obtained if indicated by the clinical course. 
Patients were discharged the same day or on the day following the procedure. Aspirin 100 mg/day was 
given long term and clopidogrel 75 mg/day was prescribed for 12 months. 
Quantitative coronary angiography evaluation was obtained in multiple views. Analyses were per-
formed before, during and after the procedure after administration of intracoronary nitrates. For patients 
with angiographie follow-up, restenosis was defined as a 50 percent or more reduction of the luminal 
diameter occurring within the 5 proximal and distal segment millimeters of the stented. 
Clinical follow-up was obtained by a visit or by telephone contact with the patient or his/her referring 
physician. The pre-specified primary end point was a composite of major adverse cardiac events (MACE), 
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defined as cardiac death, myocardial infarction, and 
ischemia-driven revascularization of the target 
lesion. Secondary end points included ischemia-
driven revascularization of the target lesion (TLR), 
target-vessel revascularization (TVR), and target-
vessel failure (TVF). TLR and TVR were considered 
to be driven by ischemia if the stenosis of the target 
lesion or vessel was > 50% on the basis of quantita-
tive coronary angiography in the presence of isch-
emic signs or symptoms, or if there was a stenosis 
of >70% in the absence ofischemic signs or symp-
toms. TLR was defined as a repeated revasculariza-
tion based on a stenosis within the stent or within 
the 5-mm borders proximal or distal to the stent. 
The diagnosis of myocardial infarction (MI) after 
the intervention was established whenever new Q-
waves of at least 0.4 seconds duration in at least 2 
contiguous leads appeared on the electrocardiogram 
with an elevated creatine kinase MB fraction level 
or in the absence of pathologie Q waves, an eleva~ 
tion in creatine kinase levels to more than twice the 
upper limit of normal with an elevated creatine 
kinase MB or troponin I level. Stent thrombosis was 
defined as an acute coronary syndrome with angio-
graphie documentation of either target vessel occlu-
sion or thrombus within or adjacent to the previously 
successfully stented segment. 
Statistical Analysis 
Values are expressed as mean± standard deviation. 
The Fischer's exact test was used for statistical 
analysis. A two tail p value <0.05 was considered 
to be of statistical significance. 
Results 
During the study period 3802 percutaneous inter-
ventions were performed. Hundred and four 
patients underwent plained old balloon angioplasty 
(POBA) because offocalrestenosis. Twenty seven 
patients (0.1 %) patients who had in-SES restenosis 
which could not be treated solely with POBA, were 
included in the registry. The demographic and 
clinical data are presented in Table 1. All patients 
were already treated with dual antiplatelet agents 
(aspirin and clopidogrel). This combination is 
routinely administered for 1 year after implantation 
of SES. Ahighpercentage (37%) of patients were 
diabetics and more than a halfhad 3 vessel disease. 
The angiographie characteristic of the lesion are 
presented in Table 2. Most of the patients had a 
pattern of diffuse restenosis (54%), although 
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Table 1. Demographic data. 
Gender (male/female) 
Mean age (yrs) 
Diabetes (n (%)) 
Hypertension (n (%)) 
Heredity (n (%)) 
Dyslipidemia (n (%)) 
Smokers (n (%)) 
1-vessel disease (n (%)) 
2-vessel disease (n (%)) 
3-vessel disease (n (%)) 
Previous AMI (n (%)) 
Previous CABG (n (%)) 
Previous PTCA (n (%)) 
Stable angina (n (%)) 
Unstable angina (n (%)) 
Silent ischemia (n (%)) 
21/7 
65± 14 
10 (37%) 
13 (48%) 
10 (37%) 
18(67%) 
10 (37%) 
6 (22%) 
7 (26%) 
14 (52%) 
4 (15%) 
7 (26%) 
27 (100%) 
12 (44%) 
9 (34%) 
6 (22%) 
proliferative restenosis was rare (7% ). In 7 patients 
the stent was located in a saphenous vein graft. The 
procedure was successful in all patients and a mean 
number of 1.1 ± 01 stents/patients were implanted. 
The minimal lumen diameter increased from 
0.73 ± 0.44 mm to 3.27 ± 0.5 mm. No patients 
experienced in-hospital complications. 
Atthe end of ameanfollow-up of 14+ 7 months, 
19 patients were still free of adverse events (70% ). 
Major cardiac adverse events (MACE) occurred in 
8 patients (30%). Two patients died, one from a 
Table 2. Angiographie data. 
Reference 
diameter 
(mm± SD) 
MLD (mm± SD) 
Percent stenosis 
(%lumen 
diameter ± SD) 
Lesion length 
(mm ±SD) 
Number of stents 
Type of 
restenosis (n (%)) 
Focal Diffuse 
Proliferative 
Location of ISR 
Native vessel 
SVG 
Mean delay after 
stenting (months) 
Pre-procedure Post-procedure 
3.4 ± 0.6 3.64 ± 0.54 
0.73 ± 0.44 
78± 14 
15±4 
1.1 ±0.1 
9 (34%) 
16 (59%) 
2 (7%) 
21 7 
7±2 
3.27 ± 0.50 
11±5 
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cardiac cause and one from a non cardiac cause. 
Six patients required additional revascularisation, 
4 (15%) had a target lesionrevascularisation (TLR), 
one ( 4%) had a target vessel revacularisation (TVR) 
and one ( 4%) underwent CABG. Among the patient 
requitring TLR, 2 (50%) had a focal restenosis. 
Even rare, in-stent retenosis following SES 
implantation remains a clinical relevant problem 
in 4 to 10% of the treated population. Several 
approaches exist to overcome this drawback like 
balloon angioplasty, brachytherapy, stent in stent 
implantation or rotational atherectomy. As reste-
nosis occurred in SES, it seemed logic to implant 
a second SES in the first one. The concept is that 
a second implant with an additional dose of siro-
limus on the same lesion might be more efficient 
than the first one, the reason for this inefficiency 
remaining unclear. In addition very few data are 
actually available in the literature about the re-SES 
treatment. It could, thus, be interesting and impor-
tant to have long-term data on this approach. Our 
group of patient is a somewhat different from the 
real world population with more diabetics ( almost 
40%) and patient with saphenous vein graft dis-
ease. However this is not surprising since diabet-
ics and patients with SVG angioplasty are more 
proue to have restenosis even after SES implanta-
tion (5). Our data confirm the feasibility and the 
safety of this procedure and our results are very 
similar to the 24% of MACE, at 8 months, recently 
reported by Torguson et al. in a group of patients 
with re-SES, and are consistent with data from 
Lemos PA et al. who reported a MACE rate of 
29.2% at 9-month follow-up in DES-patients with 
in-stent restenosis (9). The long-term clinical 
outcome after re-SES is not as good as after SES 
implantation for de-novo stenosis since the 
Table 3. Clinical outcome at a mean follow-up of 14 ± 7 
months. 
Number of patients 
Cardiac death 1 (4%) 
De a th 1 (4%) 
Ml 1 (4%) 
TLR 4 (15%) 
1 (4%) 
CABG 1 (4%) 
Event-free proportion 19 (70%) 
Abbreaviations: TLR: targe! lesion revascularisation; CABG: coro-
nary artery bypass grafting; Ml: myocardial infarction. 
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incidence of MACE is approxîmately 30%, mainly 
due to a second restenosis. This is not surprising since 
most of our patients had complex (proliferative or 
diffuse) restenosis. However, even focal restenosis 
can recurred as we have seen in 2 of our patients. For 
non-diabetic patients we can hypothesize that the 
pattern of the lesion (non-focal, focal, proliferative, 
diffuse) as already documented for any DES (6), or 
the e:fficiency of the stents (how and how long the 
drug is delivered, how the stent is set in etc.) could 
give an explanation for the recurrence of the stenosis. 
Paclitaxel stent implantation could be an alternative, 
as these stents have been shown to be efficient in 
diabetic patients. However, we decided not to use 
these stents to avoid interaction due the application 
of several different drugs on the same site. 
Our study confirms that re-SES placement is 
safe and feasible. The technique allows to treat most 
of the patients with in-SES restenosis. However, 
this does not represent a miraculous solution but an 
alternative to other percutaneous or surgical options. 
It should be reserve to patients with diffuse or 
proliferative restenosis. In patients with focal reste-
nosis, balloon angioplasty will certainly remain the 
best option, at least for a first restenosis. 
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